Roche wins over Amgen at ITC in Cera matter

Reuters: An administrative law judge at the U.S. International Trade Commission has determined that Roche AG can import its experimental drug peg-EPO, also known as Cera (rival to EPOGEN), under a special exception for clinical trials.

Amgen is also contesting the matter in the U.S. District Court of Massachusetts, in Boston.


from finanzen.net:

An Administrative Law Judge [ALJ] at the U.S. International Trade Commission [ITC] issued a summary determination that Roche's importation and use of peg-EPO in the United States todate are subject to a clinical trial exemption to patent infringement. This decision will become final within thirty days unless modified bythe Commission. The ALJ made no determination with respect to the merits of Amgen's claim that Roche's future importation and sale of peg-EPO will infringe Amgen's patents. The decision does not prevent Amgen from re-filing its complaint at a later time.